<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116685</url>
  </required_header>
  <id_info>
    <org_study_id>OC5-DB-02</org_study_id>
    <nct_id>NCT03116685</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria</brief_title>
  <official_title>A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OxThera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OxThera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of OC5 in patients with PH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma oxalate concentration after 52 weeks of treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in total plasma oxalate concentration after 52 weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Primary Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxabact OC5 - Oxalobacter formigenes HC-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oxabact OC5 - Oxalobacter formigenes HC-1</intervention_name>
    <description>Active study drug</description>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent (as applicable for the age of the subject)&#xD;
&#xD;
          2. A diagnosis of PH (as determined by standard diagnostic methods).&#xD;
&#xD;
          3. eGFR &lt; 90 ml/min/1.73 m2. The Schwartz formula will be used to estimate GFR for&#xD;
             children (age below 18), and CKD-EPI formula will be used for adults (age 18 or&#xD;
             above).&#xD;
&#xD;
          4. Plasma oxalate concentration ≥10 μmol/L in total plasma oxalate.&#xD;
&#xD;
          5. Male or female patients ≥ 2 years of age.&#xD;
&#xD;
          6. Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months&#xD;
             prior to screening and must not change the dose during the study. Patients not&#xD;
             receiving vitamin B6 at study entry must be willing to refrain from initiating&#xD;
             pyridoxine during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to swallow size 4 capsules.&#xD;
&#xD;
          2. Subjects that have undergone transplantation (solid organ or bone marrow).&#xD;
&#xD;
          3. Patients requiring dialysis or at immediate risk for kidney failure or expected to be&#xD;
             in need of dialysis during the study period.&#xD;
&#xD;
          4. The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery&#xD;
             or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory&#xD;
             bowel disease and short-bowel syndrome.&#xD;
&#xD;
          5. Use of antibiotics to which O. formigenes is sensitive. (This includes current&#xD;
             antibiotic use, or antibiotics use within 14 days of initiating study medication).&#xD;
&#xD;
          6. Current treatment with a separate ascorbic acid preparation.&#xD;
&#xD;
          7. Pregnant women (or women who are planning to become pregnant) or lactating women.&#xD;
&#xD;
          8. Women of childbearing potential who are not using adequate contraceptive precautions.&#xD;
             Please see section 7.3 regarding requirements for contraception.&#xD;
&#xD;
          9. Presence of a medical condition that the Investigator considers likely to make the&#xD;
             subject susceptible to adverse effect of study treatment or unable to follow study&#xD;
             procedures or any condition that is likely to interfere with the study drug mechanism&#xD;
             of action (such as abnormal GI function).&#xD;
&#xD;
         10. Participation in any interventional study of another investigational product,&#xD;
             biologic, device, or other agent within 60 days prior to the first dose of OC5 or not&#xD;
             willing to forego other forms of investigational treatment during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindernierenzentrum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hédi Chaker University Hospital</name>
      <address>
        <city>Sfax</city>
        <zip>3000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahloul University Hospital</name>
      <address>
        <city>Sousse</city>
        <zip>4054</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Nicolle University Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Children's Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 3, 2021</returned>
    <submitted>November 11, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

